• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

    66.18 +1.79 (+2.78%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 690,852
    Open 64.00
    Bid (Size) 66.18 (12)
    Ask (Size) 66.33 (7)
    Prev. Close 64.39
    Today's Range 63.90 - 66.54
    52wk Range 35.17 - 68.58
    Shares Outstanding 63,494,892
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
    Via Benzinga
    RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) – A Strong Growth Candidate Meeting Minervini’s Criteria
    RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) meets Minervini’s Trend Template with strong technicals and high revenue growth, making it a candidate for growth investors. 
    Via Chartmill

    Performance

    YTD
    +10.2%
    +10.2%
    1 Month
    +2.7%
    +2.7%
    3 Month
    +21.1%
    +21.1%
    6 Month
    +10.4%
    +10.4%
    1 Year
    +82.8%
    +82.8%

    More News

    Read More
    Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
    Via Benzinga
    Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Earnings Scheduled For May 7, 2025
    Via Benzinga
    Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts
    Via Benzinga
    Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
    Via Benzinga
    Earnings Scheduled For February 26, 2025
    Via Benzinga
    7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
    Via Benzinga
    Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish
    Via Stocktwits
    Topics Government
    Exposures Political Product Safety
    Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder
    Via Benzinga
    Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Analyst Expectations For Rhythm Pharmaceuticals's Future
    Via Benzinga
    Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
    Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
    What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 66.18
    When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 06/05/25 04:00 PM ET
    What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 4.20B
    How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
    Rhythm Pharmaceuticals, Inc. - Common Stock has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.